Drug Delivery System
Online ISSN : 1881-2732
Print ISSN : 0913-5006
ISSN-L : 0913-5006
Feature articles “Recombinant virus for gene therapy and vaccine” Editor : Hiroyuki Mizuguchi
The research for development of polyvalent lived vaccine based on current varicella vaccine
Tetsuo Koshizuka, Yasuko Mori
Author information
Keywords: Varicella vaccine, varicella-zoster virus, polyvalent vaccine, mumps virus, recombinant virus
JOURNAL FREE ACCESS

2009 Volume 24 Issue 6 Pages 592-598

Details
Download PDF (379K)
Download citation RIS

(compatible with EndNote, Reference Manager, ProCite, RefWorks)

BIB TEX

(compatible with BibDesk, LaTeX)

Text
How to download citation
Contact us
Abstract
Varicella-zoster virus (VZV) infection is a causative agent of varicella and zoster. Varicella vaccine has been developed to reduce the morbidity of varicella. The Oka vaccine is the only attenuated live varicella vaccine permitted for use by WHO.
Recently we have generated a recombinant virus expressing mumps virus (MuV) HN protein based on the varicella vaccine. The recombinant virus could induce neutralizing antibodies against both VZV and MuV in guinea pig, thus indicating that the virus may be a candidate for polyvalent live vaccine against MuV and VZV infection.
Here we have summarized about the Oka vaccine, the recombinant virus and the application for a polyvalent live vaccine of the recombinant virus.
Content from these authors
© 2009 Japan Society of Drug Delivery System
Previous article Next article
Favorites & Alerts

Recently viewed articles
Share this page
feedback
 Top